Skip to main content
Equibles

David McClung

CFO

BioCardia, Inc. (BCDA)

Equibles does not estimate personal net worth.

Get an email with a short summary when BioCardia, Inc. publishes a filing, an earnings call transcript or a press release.

Get BCDA alerts

About David McClung

David McClung is recorded as CFO at BioCardia, Inc. (BCDA). The newest filing on record that lists David McClung as CFO at BioCardia, Inc. (BCDA) is dated November 3, 2025. The proxy statement of BioCardia, Inc. reports total compensation of $354,942 for David McClung in fiscal 2024, including a base salary of $354,942. Disclosed compensation is on record for 5 fiscal years. David McClung has spoken on 17 earnings calls across 1 company, most recently for BioCardia, Inc. on August 12, 2026. BioCardia, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BioCardia, Inc. includes Peter Altman (CEO and Board Member) and Marvin Slosman (Board Member).

David McClung on recent calls

“I'll now review the highlights of our financial results for the quarter and six months into June 30th, 2026. Net cash used in operations during the three months into June 2026 was approximately $1.7 million, increased slightly from the $1.6 million used in the three months into June 2025.”
CFO, BioCardia, Inc. Q2 FY2026 Earnings Call ·
“Here are the highlights of our financial results for the quarter ended March 31, 2026. Total expense decreased by $460,000 quarter-over-quarter to $2.3 million in the first quarter of 2026 compared to $2.7 million in the same quarter of 2025.”
CFO, BioCardia, Inc. Q1 FY2026 Earnings Call ·
“I'll now provide an overview of our financial results for the year ended December 31, 2025. Total expenses increased approximately 3% year-over-year to $8.3 million in 2025 compared to $8.1 million in 2024.”
CFO, BioCardia, Inc. Q4 FY2025 Earnings Call ·
“CARDI AMP heart failure two trial advances include using the cell population analysis at screening to define treatment dose and improvements to the Helix system, including our FDA-approved morphDNA steerable guide platform.”
CFO, BioCardia, Inc. Q3 FY2025 Earnings Call ·
“I'd like to take a moment to review the highlights of our financial results for the quarter and the six months ended June 30, 2025. Research and development expenses increased to approximately $1.4 million for the three months ended June 2025 from approximately $0.8 million in the three months ended June 2024.”
CFO, BioCardia, Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at BioCardia, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 BioCardia, Inc. (BCDA) $354,942 $354,942
2023 BioCardia, Inc. (BCDA) $370,858 $469,469
2022 BioCardia, Inc. (BCDA) $382,000 $565,104
2021 BioCardia, Inc. (BCDA) $364,313 $668,409
2018 BioCardia, Inc. (BCDA) $300,000 $594,982

Recent activity

Show 5 earlier activities